Breakout Session I

Breakout Session Options:

  • Coping with Financial Toxicity: The Cost of Treatment Hurts, Too
  • Contracting for Industry-Sponsored Oncology Trials
  • Understanding Cell Gene Therapy & How to Become a Cell Therapy Site


Coping with Financial Toxicity: The Cost of Treatment Hurts, Too
This discussion-style panel will share examples of how sites, sponsors, and CROs manage financial toxicity for patients as well as participation burden, patient benefits, and the number of technologies we are asking patients to use in trials. Understand the challenges surrounding patient financial burden and how we can collaborate to fix it!

Peter Fredette,
Director, Clinical Partnerships Liaison, EQRx

Adrian McDonald, BSc(Hons)Nursing, Director, Site Optimization and Engagement, Illingworth Research Group™
Nkechi Moghalu, Associate Director, Site Engagement Management, Daiichi-Sankyo
Ari Oglesby, CCRP,
Associate Director, Clinical Research Programs,  University of California, San Francisco
Kathleen Phan, A
ssociate Director, Oncology Site Operations, Care Access



Contracting for Industry-Sponsored Oncology Trials
Join us to discuss the most common sticking points in oncology trial CTAs. This session will review and consider common best practices, the multiple options for common difficult clauses, evidence-based confidentiality concerns, standardization efforts, workable payment schedules, and common unforeseen contracting mishaps.

Kathleen Hurtado, Associate Vice President, Cancer Treatment Centers of America

Daniel Fox, MPH, PhD, 
Founder/CEO, Clinical Research, Payment Network; Land of Lincoln Clinical Research
Adam Penna, JD,
Associate Director, Clinical Research, Merck 


Understanding Cell Gene Therapy & How to Become a Cell Therapy Site
Cell therapies are designed to improve the immune system’s ability to fight cancer. This very specific type of therapy requires more from the site, but what exactly do you need to become a cell therapy site? In this session, we will talk about what community oncology centers need to do to offer cell therapy.

Evette Riegel,
Vice President, Project Delivery, Hematology/Oncology, PPD, part of Thermo Fisher Scientific

Patrick Conley, MS, CBSP, NREMT, 
Director of IBC Operations, Clinical Biosafety Services
Daniel Kavanagh, PhD, RAC, Senior Scientific Advisor, Gene Therapy, WCG
Nojan Namakian,
Executive Director of Clinical Trial Activation & Strategic Partnerships, City of Hope
Kathy Scott, Associate Director, Site Alliances, Parexel



Location: See App for Room Location Date: April 1, 2023 Time: 10:30 am - 11:30 am